Johnson & Johnson to Tap into huge Alzheimer's Market

July 9, 2009

Print Send to a Friend Tweet this Analysis

Analysis by: GLG Expert Contributor
Analysis of: Johnson & Johnson puts $1.5bn in Elan for Alzheimer's vaccine
Published at: www.eurobiotechnews.eu

Summary

J&J hopes to take into the huge marketplace for Alzheimer's treatments.

Analysis

The current Alzheimer's therapies, Aricept, Razadyne, Namenda, and Exelon can only hope to slow the progression of the disease. J&J hopes that their new treatment may actually stop or reverse the progression of this devistating illness in patients.

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

This author consults with leading institutions through GLG

Contributed by a Member of the GLG Healthcare Councils

Report a Concern

Similar Analyses

MoNuDin has the potential of change for future ALS patients

Potential ALS Therapy Has Promise but Still a Way to Go

Ampyra (Fampridine) Announced to be Available March 2010

View all analyses on this article Request a News Analysis

Share this Analysis

| More

Subscribe to Updates

By RSS

This author consults with leading institutions through GLG

Engage this author or other Healthcare experts: Describe your request

Are you a Healthcare expert?

Join a leading network of experts, get exposure to the most influential leaders in your community, and participate in the world's largest marketplace of expertise.

Apply to become a Council Member and share your expertise.